The patent cliff and a reducing drug pipeline are the two biggest challenges faced by innovator companies today. With the expiry of blockbuster drugs and early entry of generics, the pharmaceutical industry has lost about $157 billion in sales between 2010 and 2015. This is hampering the industry’s ability to fund drug development programs. Until about two decades ago, most drugs had an effective patent life of about 17 years, but changes to regulatory requirements and challenges by generic companies has resulted in only about 7 to 11 years of market exclusivity for innovators’ drugs.
The Clinical Data Interchange Standards Consortium (CDISC) and the Infectious Diseases Data Observatory (IDDO) announce the availability of a new standard to assist in the collection, aggregation and analysis of Ebola virus disease (EVD) research data